Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.
Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing.
STK11 co-mutation and KEAP1 Wild-Type (local confirmation)
Treatment naïve or have received at least 1 prior standard therapy for advanced NSCLC
ECOG 0-1
Has CNS metastases or carcinomatous meningitis, except treated CNS metastases with no evidence of radiographic progression or hemorrhage for at least 28 days
Any severe and/or uncontrolled medical conditions
Active infection requiring systemic treatment within 7 days
Therapeutic radiation therapy within 3 weeks of study day 1